Novel Kyowa Kirin antibody progresses in lymphoma
This article was originally published in Scrip
Kyowa Hakko Kirin's CCR4-targeting antibody KW-0761 has moved into Phase II development in Japan as a treatment for adult T-cell lymphoma.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.